Bio-Techne (TECH) prevailed on another claim that Miltenyi Biotec KG commercialized antibodies developed based on information obtained by reverse engineering Bio-Techne’s proprietary R&D Systems branded NKG2C/CD159c antibodies. This follows a similar case from 2023, where Miltenyi was found to have reversed engineered and commercialized Bio-Techne’s proprietary R&D Systems branded TIGIT and CCR-7 antibodies. Bio-Techne took legal action against Miltenyi in the Cologne Regional Court, Germany, after discovering that the variable regions of Miltenyi’s NKG2C/CD159c antibodies were 100% identical to the R&D Systems antibodies. In addition to finding that Miltenyi has been marketing and selling these reverse engineered antibodies, the court determined that Bio-Techne is entitled to monetary damages related to sales of the reverse engineered antibodies, reimbursement for Bio-Techne’s costs incurred to demonstrate that Miltenyi copied Bio-Techne’s antibodies and additional detailed information regarding Miltenyi’s unlawful reverse engineering activities. Miltenyi may appeal the Court’s ruling.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TECH:
- Bio-Techne signs co-marketing and co-promotion agreement with Waters
- Bio-Techne signs distribution agreement with MedSanTek in Turkey
- Gemini Bioproducts acquires selected FBS product rights from Bio-Techne
- Bio-Techne announces partnership with Leader Life Sciences
- Bio-Techne, ALZpath announce strategic partnership
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
